ClinicalTrials.gg
WithdrawnNCT02367690Updated Jan 20, 2023

Study of Safety, Tolerability, and Pharmacokinetics of Topical Selinexor (KPT-330) Diabetic Foot Ulcer (DFU) Patients

A Phase 1/2 interventional study of Selinexor and Standard-of-Care in Diabetic Foot Ulcers, sponsored by Karyopharm Therapeutics Inc. Withdrawn at 1 site in New Zealand. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2023-01-20.

Sponsored by Karyopharm Therapeutics Inc · Phase 1/2, Interventional, and Treatment

Why this study was withdrawn
Due to enrollment challenges \& improved SOC during run-in phase; no patients received KPT-330. Withdrawal is not a consequence of any safety concern.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
0
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Study summary

Patients with eligible diabetic foot ulcers will be screened, treated, and followed for complete ulcer closure. This is a randomized trial. All patients will receive standard-of-care treatment. Additionally, some patients will receive treatment with topical Selinexor gel and some will receive topical placebo gel.

Read the detailed description

Approximately 30 patients who meet the eligibility criteria will be enrolled. Eligible patients with diabetic foot ulcers will be screened, randomized, treated, and followed for complete ulcer closure.

After screening, qualified patients will be treated for up to 12 weeks. Patients who achieve complete ulcer closure will be followed for an additional 12 weeks.

All patients will receive standard-of-care treatment. After randomization some patients will be treated with topical Selinexor gel twice weekly and some patients will be treated with a topical placebo gel twice weekly. Patients receiving Selinexor will be assigned to a sequential treatment cohort, either a 10 μM (μmol/L), 30 μM, or 70 μM dose.

02

Conditions studied

  • Diabetic Foot Ulcers

Keywords

  • Diabetes
  • Foot Ulcers
  • DFU
  • KPT-330
  • Selinexor
  • Karyopharm
03

In context

Diabetic Foot

1,079 studies on the registry are indexed under Diabetic Foot; 222 are open to participants now.

Browse Diabetic Foot studies →

Lead sponsor

Karyopharm Therapeutics Inc is the lead sponsor of 37 studies on the registry; 4 are open to participants now.

Of its 18 completed or terminated interventional studies of FDA-regulated products, 16 (89%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patient has a clinical diagnosis of Type I or Type II diabetes mellitus with an ≤ 10.0 and has a ≤40.
  • The DFU(s) to be treated must be:

    • Anatomically discrete,
    • Non-healing, but has persisted for ≤12 months
    • Measures 1 cm2 ≤ area ≤ 5 cm2 following debridement,
    • Has a Wagner Grade 1 (i.e., not involving bone, muscle, tendons, or ligaments),
    • The Target DFU is located distal to the ankle (i.e., below the malleolus), and
    • Is able to be adequately off-loaded.
  • The patient has adequate arterial blood supply in the affected limb at screening.
  • Patient has the inability to perceive 10 grams pressure in the peri-ulcer area and other regions of the affected foot and toes using Semmes-Weinstein 5.07 monofilament at screening.

Exclusion criteria

Exclusion Criteria:

  • Patient has a foot ulcer that is clearly of non-diabetic pathophysiology.
  • Patient has more than two (2) DFUs on the target lower extremity.
  • DFU is clinically infected.
  • Patient has active osteomyelitis of the foot or active, uncontrolled, connective tissue disease
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    Cohort 1

    Cohort 1 will be randomized to one of the following treatment groups: a) Standard-of-care (SOC) + Selinexor gel, 10 μM , b) SOC + vehicle gel c) SOC alone.

    Drug: Selinexor · Other: Standard-of-Care · Other: Vehicle Gel

  • Experimental
    Cohort 2

    Cohort 2 will be randomized to one of the following treatment groups: 1. Standard-of-care (SOC) + Selinexor gel, 30 μM 2. SOC + vehicle gel 3. SOC alone.

    Drug: Selinexor · Other: Standard-of-Care · Other: Vehicle Gel

  • Experimental
    Cohort 3

    Cohort 3 will be randomized to one of the following treatment groups: 1. Standard-of-care (SOC) + Selinexor gel, 70 μM 2. SOC + vehicle gel 3. SOC alone.

    Drug: Selinexor · Other: Standard-of-Care · Other: Vehicle Gel

Interventions

  • Topical gel

    Also known as: KPT-330

  • OtherStandard-of-Care

    Surgical debridement, sterile saline rinses, and dressing changes.

    Also known as: SOC

  • OtherVehicle Gel

    Topical vehicle gel with no active ingredients.

06

What researchers measure

Primary outcomes

  1. Presence of Local Skin Reactions (LSR)

    Presence of local skin reactions (erythema, edema, pain, tenderness, induration, swelling, wound drainage, purulence, odor, cellulitis, callus, and maceration) within 4 cm of the diabetic foot ulcer wound edge.

    Time frame: 84 days

Secondary outcomes

  1. Ulcer Closure

    Proportion of patients in each treatment group with complete ulcer closure of the target diabetic foot ulcer.

    Time frame: 84 days

07

Study locations

1 site
  • South Pacific Clinical Trials
    Auckland, 0610, New Zealand
08

References and documents

Individual participant data

Plan to share: Yes

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2015, a primary completion of May 2015 and a completion of Sep 2015. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 9, 2015
First posted
Feb 20, 2015
Start
Jan 2015
Primary completionActual
May 2015
CompletionActual
Sep 2015
Last update
Jan 20, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 20, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02367690
Responsible party
Sponsor
First posted
Feb 20, 2015
Start date
Jan 2015
Primary completion
May 2015
Completion
Sep 2015
Last update
Jan 20, 2023

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Jan 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Selinexor

Start the discussion